On September 9, 2021, the Board of Directors of Syros Pharmaceuticals, Inc. appointed Deborah Dunsire, M.D., as a Class II director. Dr. Dunsire was also appointed to the Compensation Committee and the Research and Development Committee of the Board. Dr. Dunsire, age 59, has more than 30 years of clinical, commercial, and international management experience from the biotech and pharmaceutical industry, primarily in the fields of oncology and CNS. Dr. Dunsire currently serves as President and Chief Executive Officer of H. Lundbeck A/S, a public biopharmaceutical company, and has held this position since September 2018.